Protocol summary

Study aim
Determination of the Effect of Nanocorcumin Supplementation Compared to Placebo on the severity of diabetic sensorimotor polyneuropathy in type 2 diabetic patients.
Design
This study is conducted on 80 patients with diabetic polyneuropathy who have been admitted to the Diabetes Research Center.Patients are randomly divided into two groups: intervention and control groups and each participant is allocated a code.
Settings and conduct
This study is a double-blind, randomized, clinical trial on diabetic patients with neuropathy in Diabetic Research Center of Kermanshah University of Medical Sciences.Patients will be randomized into two groups of supplementation with curcumin and placebo for 8 weeks. Curcumin supplements are provided in the form of 80 mg capsules. A supplement will be consumed daily in the form of a capsules .Consuming supplement has been followed up in person every month .Meanwhile, once a week, the use of supplements is followed up by phone call.At the beginning and end of the study, from each person will taken two 24-hour meal reminders , and physical activity will be reviewed using the International Short Form Physical Activity Questionnaire (IPAQ).To determine the severity of neuropathy, the Toronto questionnaire will be used. Anthropometric evaluations are also performed. The study will be double blind, and the researcher and the patient will not get any supplementation information.
Participants/Inclusion and exclusion criteria
In this study, non-insulin type 2 diabetic patients with mild diabetic sensorimotor polyneuropathy will be included. People with other illnesses or those with neuropathies other than diabetic polyneuropathy will not be included in the study.
Intervention groups
Receiving nano-curcumin supplements formed of nanomixel curcumin particles, an effective ingredient in turmeric, by the intervention group and receiving placebo formed of all formulations of the drug except of curcumin , by the control group in the form of gel capsules of 80 milligrams from the Minoo Pharmaceutical Company Are being prepared. A 80 mg supplement will be consumed daily as a lunch capsule.
Main outcome variables
Severity of sensory-motor movement polyneuropathy; Blood pressure levels of fasting blood glucose, HbA1C and BS2hpg

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20140413017254N5
Registration date: 2017-12-28, 1396/10/07
Registration timing: prospective

Last update: 2017-12-28, 1396/10/07
Update count: 0
Registration date
2017-12-28, 1396/10/07
Registrant information
Name
Gity Sotoude
Name of organization / entity
Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 4293 3333
Email address
gsotodeh@tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-01-21, 1396/11/01
Expected recruitment end date
2018-08-23, 1397/06/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Effect of Nano curcumin supplementation on the severity of diabetic sensorimotor polyneuropathy in type 2 diabetic patients : a double- blind randomized clinical trial
Public title
Effect of Nano curcumin on the severity of diabetic sensorimotor polyneuropathy
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion criteria:
Age between 30 to 60 years old desiration to participate in the study Body mass index between25 - 39.9 Non-insulin diabetic patients type 2 Detection of mild sensorimotor polyneuropathy by using the Toronto questionnaire (score 6-8)
Exclusion criteria:
Follow a special diet during last month Sensitivity to curcumin Pregnancy and lactation Eat any nutritional supplement, vitamin and mineral supplement last month History of gastrointestinal ulcer and bile duct There are neuropathies other than the sensory-motor polyneuropathy diabetic diagnosed by a neurologist Take gabapentin and any medication Diseases diagnosed, such as cancer, liver, kidney, autoimmune diseases, inflammatory, thyroid and nervous and cardiovascular diseases, and drug use associated with these diseases
Age
From 30 years old to 60 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
For random allocation of individuals by statistic expert, permute-block randomization will be used for the two groups of study; thus, four blocks of AABB, ABAB, ABBA, BBAA, BABA, and BAAB are selected 20 times randomly and with placement, and The letters of the selected blocks will be written after each other. Stratified randomization will be used to control age and gender variables, based on the following categories: age (30-45, 46-60) and gender (male, female).
Blinding (investigator's opinion)
Double blinded
Blinding description
The researcher and the patient do not have any information on the type of supplement that they receive and they are prepared in the same way as in the form of tablets and supplements like nano-curcumin. A person who is not aware of the packet content will be asked to complete the naming of the supplement and the placebo in groups A and B. After collecting data at the end of the study, the codes of supplements will be specified for the researchers
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Tehran University of Medical Sciences
Street address
Central Building of Tehran University of Medical Sciences, Ghods st., Keshavarz Blv., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1417653761
Approval date
2017-11-01, 1396/08/10
Ethics committee reference number
IR.TUMS.VCR.REC.1396.3838

Health conditions studied

1

Description of health condition studied
Diadetic polyneuropathy
ICD-10 code
E11.43
ICD-10 code description
Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy

Primary outcomes

1

Description
The severity of neuropathy in the Toronto questionnaire
Timepoint
Before the intervention, After intevention
Method of measurement
Toronto questionnaire

Secondary outcomes

1

Description
Fasting Blood Sugar
Timepoint
Before the intervention, After the intervention
Method of measurement
KIT

2

Description
Blood sugar 2 hour after meal
Timepoint
Before the intervention, After the intervention
Method of measurement
KIT

3

Description
HBA1C
Timepoint
Before the intervention, After the intervention
Method of measurement
KIT

Intervention groups

1

Description
Intervention group: Supplement that made of nano mucosal curcumin, an effective ingredient in turmeric, is prepared in the form of gelatin capsules of 80 milligrams from the Minoo Pharmaceutical Company. A 80 mg supplement will be consumed daily as a lunch capsule.
Category
Treatment - Drugs

2

Description
Control group: Placebo, which consists of all drug formulation components except the effective curcumin agent, is prepared in the form of gel capsules of 80 mg from Minoo Pharmaceutical Company. A 80 mg supplement will be consumed daily as a lunch capsule.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Taleghani Therapeutic Center
Full name of responsible person
مهرعلی رحیمی
Street address
Taleghani Therapeutic Center, Shahid Beheshti Blvd., Kermanshah, Iran
City
Kermanshah
Province
Kermanshah
Postal code
3836798490
Phone
+98 38 3679 8490
Email
Taleghani_Hospital@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Mohammad Ali Sahraeian
Street address
Ghods St., Keshavarz Blvd., Central Organization of Tehran university of Medical Sciences
City
Tehran
Province
Tehran
Postal code
2188955698
Phone
+98 21 8163 3698
Email
Info_snsd@tums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Sara Asadi
Position
Master of nurition
Latest degree
Bachelor
Other areas of specialty/work
Nutrition
Street address
School of Nutrition, Tehran University Medical Sciences, Naderi St., Keshavar Blvd., Tehran
City
Tehran
Province
Tehran
Postal code
1439957181
Phone
+98 21 8895 5742
Email
sr.asadi11@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Gity Sotodeh
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
School of Nutrition, Tehran University of Medical Sciences, Naderi St., Keshavar Blvd., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
2188955698
Phone
+98 21 8895 5742
Email
gsotodeh@tums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Sara Asadi
Position
Master of Nutrition
Latest degree
Bachelor
Other areas of specialty/work
Nutrition
Street address
School of Nutrition, Tehran University of Medical Sciences, Naderi St., Keshavar Blvd., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
2188955698
Phone
+98 21 8895 5742
Email
sr.asadi11@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...